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ABSTRACT
Bone and mineral disorders (BMDs) in chronic kidney disease (CKD)  are increasingly being studied, and 
prophylaxis and treatment are conducted, but they still remain one of the most severe systemic illnesses in 
patients with CKD.
In patients with end-stage CKD and secondary hyperparathyroidism, accompanying metabolic disorders 
of calcium and phosphorus homeostasis may lead to pathological changes in bone and blood vessels, which 
increase the risk of bone fractures and cardiovascular (CV) events. High levels of parathyroid hormone 
(PTH), calcium and phosphorus are associated with increased morbidity and mortality in dialysis patients.
Dialysis treatment is a renal replacement method that continues the life of patients with CKD, temporarily 
improving existing bone pathology, but it more often accelerates its progression. Therefore, the symptoms, 
developmental and complications of BMD-CKD are demonstrated and manifested in patients with extracor-
poreal treatment.
Treatment of BMD requires constant monitoring of Ca-P exchange, PTH, serum of Vitamin D levels and the 
protein bone markers - osteocalcin, bone alkaline phosphatase.
Despite the systemic use of active metabolites of vitamin D, phosphate binders and calcimimetics, in many 
patients with secondary hyperparathyroidsm, inadequate biochemical control has been observed.
In the Dialysis Clinic at St. Marina University Hospital, Varna, two groups of patients on hemodialysis (HD) 
and with CKD - 2/3 stage with secondary hyperparathyroidism, were followed and had their serum biomark-
er levels compared - PTH, bone alkaline phosphatase (BAP), osteocalcin, and vitamin D. The results showed 
statistically significant differences between the two groups in the investigated serum levels of the indica-
tors.
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INTRODUCTION
In patients with end-stage chronic kidney dis-
ease (CKD) and secondary hyperparathyroidism, 
accompanying metabolic disorders of calcium and 
phosphorus homeostasis may result in pathological 
changes in bone tissue and vessels that increase the 
risk of bone fractures and cardiovascular disorders 
(1). High levels of parathyroid hormone (PTH), cal-
cium and phosphorus are associated with increased 
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The method for quantification of osteocalcin was a 
direct chemiluminescent immunoassay (CLIA). Di-
aSorin LIAISON® BAP OSTASE® is a one-step sup-
plemental immune hemolytic assay (IHLA) designed 
for quantification of BAP in human serum. 
The precision of the LIAISON® assay was evalu-
ated according to CLSI EP5-A2.
All blood samples for the biomarkers tested 
were taken at the beginning of the dialysis session in 
a „yellow“ vacuum – 5 ml of the blood haemolines 
before the anticoagulant was placed in the extracor-
poral system. The blood sample was centrifuged for 
10 minutes at 3600 rpm to coagulate and the serum 
was separated from the clot. Thus, the resulting se-
rum was dispensed into 2 flasks – plastic vials of 1.25 
ml, and stored at up to 6°C or frozen (-20 °C or less). 
A specialized package StatSoft Inc, USA, STATISTI-
CA Manual (data analysis on1 0.0,system), Version 
10.0, 2010 was used for statistical analysis of the data.
1. Descriptive statistical analysis – it showed a 
tabular frequency distribution of the examined 
signs, broken down by study groups, averages 
and standard deviations, 95% confidence inter-
vals of change of the mean values.
2. Student̀ s test (t-criterion) for two independent 
samples was applied to detect a statistically sig-
nificant difference in the mean of a factor in 
two patient groups.
3. Student̀ s test (t-criterion) for two paired sam-
ples was applied to detect a statistically signif-
icant difference in the mean values  of a factor 
before and after treatment.
RESULTS AND DISCUSSION
Osteocalcin is the major non-collagen protein 
in human bones. It is synthesized by the osteoblasts 
and the odontoblasts of bone tissue. The main part of 
the synthesized protein enters the extracellular bone 
matrix, which then mineralizes with the formation 
of new bone and the rest falls into the blood stream. 
Its values  are increased in metabolic bone diseases 
with accelerated bone metabolism, such as osteopo-
rosis, osteomalacia and rickets, hyperparathyroid-
ism, renal osteodystrophy, thyrotoxicosis and acro-
megaly (Fig. 1). It has low values  in cases of growth 
hormone deficiency, hypoparathyroidism, hypothy-
roidism (9). Therefore, there was a statistically signif-
morbidity and mortality in patients with second-
ary hyperparathyroidism due to dialysis. The avail-
able options for treatment of bone mineral disorders 
do not always provide adequate control of PTH, cal-
cium and phosphorus levels, and are often associat-
ed with mismatch and high incidence of discontinu-
ation (2-5).
CKD affects all key steps in vitamin D metabo-
lism, namely: production, activation and degradation 
of vitamin D and its metabolites at 25-hydroxyvita-
min D (25(OH)D) and low levels of 1,25 dihydroxyvi-
tamin D (1,25(OH)2D) (6). The loss of vitamin D in 
urine is used as a marker for vitamin D levels in pa-
tients with high proteinuria. However, it can be ex-
pected that the decrease in vitamin D would initial-
ly reduce the levels of 1,25(OH)2D, and subsequent-
ly those of the fibroblast growth factor-23 (FGF-23).
The results of a recent study of patients cate-
gorized in phenotypes based on PTH, calcium and 
phosphate levels demonstrated that phenotypically 
elevated levels of PTH, phosphate and calcium carry 
a greater risk of death or hospitalization associated 
with a cardiovascular event in comparison to pheno-
types where all three parameters are within the tar-
get values (7,8).
The use of vitamin D receptor activator in the 
pre-dialysis stage has an inhibitory effect on the ele-
vation in the serum levels of PTH at the time of di-
alysis initiation.
MATERIALS AND METHODS
The serum level of biomarkers – PTH, vit. D 
and osteocalcin, bone alkaline phosphatase (BAP) 
were monitored in two groups of patients – 28 men 
and 30 women on hemodialysis (HD) treatment at 
the Dialysis Clinic of St. Marina University Hospi-
tal, Varna; and 18 men and 29 women in pre-dialysis 
stage with CKD.
The following methods were used to screen 
iPTH, 25 OH vitamin D, osteocalcin and BAP OS-
TASE®: the LIAISON® 25 OH Vitamin D TOTAL 
test, which applies a chemiluminescent immune test 
(CLIA) technology for the quantification of 25-hy-
droxyvitamin D and other hydroxylated metabolites 
of vitamin D in human serum;  the LIAISON® Os-
teocalcin Test of DiaSorin, which is a single-step im-
munohistochemical assay (IHCA) designed to quan-
tify the osteocalcin polypeptide in human serum. 
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icant difference in the osteocalcin mean values  of pa-
tients in both groups.
Kidney Disease
Improving Global Outcomes (KDIGO) rec-
ommends maintaining PTH levels in the range of 
approximately 2 to 9 times the upper limit of nor-
mal (the proposed level of PTH from KDIGO corre-
sponds to 120 to 660 pg/mL), while calcium is main-
tained within the normal range and elevated levels of 
phosphate decreased to normal in patients with CKD 
on dialysis. 
Our study showed a significant difference in the 
values of vit. D in the two groups of patients at the 
pre-dialysis and dialysis stage (Fig.2).
Vitamin D deficiency is associated with meta-
bolic syndrome and obesity in HD patients. It is also 
associated with insulin resistance, ventricular hyper-
trophy, atherosclerosis and vascular calcifications. 
London et al. reported a feedback between ar-
terial stiffness and serum 25(OH)D and 1,25(OH)2D 
levels in dialysis patients.
According to Boudville et al. the deficiency of 
25(OH)D  is associated with muscle weakness and 
decreases in dialysis patients with a curve and a max-
imum benefit in the range of 24 to 44 ng/mL of se-
rum levels of 25(OH)D. Vitamin D deficiency is as-
sociated with metabolic syndrome and obesity (10) in 
HD patients. In patients at the pre-diaysis stage, low 
levels of vitamin D are associated with cognitive im-
pairment (11).
According to studies that report results from 
North America, Asia, Australia and New Zealand, 
approximately 50% of the patients there and over 
30% of those in Europe have available biochemical 
evidence of secondary hyperparathyroidism (SHPT) 
defined as PTH> 300 pg/mL (12).
SHPT may lead to hyperparathyroid bone dis-
ease - a common cause of bone and joint pain in di-
alysis patients, a reduction in bone mass, and an in-
crease in the risk of bone fractures (13).
Phosphorus induces the secretion of PTH by 
three mechanisms: direct stimulation of the parathy-
roid glands; induction of hypocalcemia, increased 
activity of FGF-23 (resulting in inhibition of alpha-1 
hydroxylase and lowering levels of 1,25(OH)2D).
Calcium and phosphorus metabolism disorders 
in the SHPT are thought to contribute to the calci-
fication of soft tissues and the vascular system with 
50% to 80% prevalence.
Hyperphosphatemia is one of the most com-
mon complication of CKD and, if not treated, leads to 
pruritus, bone pain, anemia, cardiovascular compli-
cations, disability, and reduced survival.The chang-
es in PTH levels relative to age (Fig. 3) are shown in 
two groups of patients – pre-dialysis with CKD – 47 
(35 women and 12 men) and patients on HD - 50 (28 
women and 22 men), who are tracked dynamically at 
the Dialysis Clinic. A statistically significant differ-
ence between the two groups was seen with Parical-
citol at a dose of 1 mg/day (Tabl. 1).
Therefore, there was no statistically significant 
difference in the mean values  of the patients in the 
two groups.
Fig. 1. Change of Osteocalcin in patients on HD and pre-
dialysis stage
Fig. 2. Values of Vit D in both patient groups
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BAP is the bone-specific alkaline phosphatase 
isoform. A glycoprotein that is found on the surface 
of osteoblasts, BAP reflects the biosynthetic activi-
ty of these bone-forming cells. It has been shown to 
be a sensitive and reliable indicator of bone metabo-
lism . Normal bones permanently undergo remod-
eling, where bone degradation or resorption is bal-
anced by bone formation. If the process becomes un-
related and the rate of absorption exceeds the rate of 
formation, resulting in bone loss, it can lead to osteo-
porosis and therefore to higher fracture sensitivity. 
High levels of BAP are associated with disabil-
ity and high mortality in dialysis patients, emphasiz-
ing the dominant effect on bone turnover. BAP se-
rum testing is of great importance for the monitor-
ing of treatment in clinical practice in patients on di-
alysis treatment.
We have studied the levels of PTH in dial-
ysis patients and patients at a pre-dialysis stage. 
Our results show a significant difference in serum 
BAP in the study groups of patients with high PTH 
and those with normal PTH (Fig. 4). 
S. Sardiwal et al. (2013), (14) suggest the use of 
bone-specific alkaline phosphatase as an alterna-
tive to PTH because this enzyme is directly related 
to bone reorganization, reflects its histomorphome-
try and can predict the healing effects of hemodial-
ysis in patients with CKD and disorders of the bone 
mineral metabolism. Bone-specific alkaline phos-
phatase hydrolyzes the pyrophosphate, which inhib-
its vessel calcification. Only bone-specific alkaline 
phosphatase is statistically significantly higher in pa-
tients with vascular calcifications than in the other 
patients (p<0.05). Multi-variance analysis demon-
strated a statistically reliable association (p<0.0001) 
between the bone-specific alkaline phosphatase log-
arithm on the one hand and the calcification of the 
vessels (15).
In addition, high levels of serum phosphate 
inhibit the activity of 25-hydroxyvitamin D3-1α-
hydroxylase, the enzyme that converts vitamin D 
into its active form - calcitriol, thereby disrupting the 
CaSR and vitamin D receptor (VDR)-inverse feed-
back that suppresses PTH. As renal function de-
creases in CKD, FGF-23 levels also increase. This is 
due at least to the decreased klotho levels in the kid-
neys and the parathyroid gland, which occur when 
kidney function decreases (16,17).
Fig. 3. Change of the PTH relative to age
Frequency table: gender_hi_PTH 
Count Cumulative - Count Percent - of Valid Cumulative % - of Valid
Woman (kod 0) 22 22 48.88889 48.8889
Мen (kod 1) 23 45 51.11111 100.0000
Tabl. 1. Dynamic change of PTH relative to sex
Fig. 4. BAP values in HD patients
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CONCLUSION
In patients with CKD, controlling PTH levels is 
recommended to keep them below 600 pg/mL to re-
duce the potential clinical consequences of SHPT as 
well as accompanying changes in calcium and phos-
phorus levels (KDIGO 2009).
Contemporary treatment aspects include vita-
min D sterols and phosphate binders, which often 
prove insufficient to achieve the target PTH, calcium 
and phosphorus levels (KDIGO 2009). Sometimes, 
the intake of vitamin D and phosphate binders is as-
sociated with a number of adverse events and chal-
lenges that may negatively affect patient adherence 
and persistence with regard to therapy (18).
Despite the widespread use of the metabolites 
of vitamin D, phosphate binders and calcificers, in 
many patients with SHPT there is inadequate bio-
chemical control. Consequently, the conclusion is 
that the lack of adherence and insufficient persis-
tence in treatment increases the risk of failed ther-
apy (19).
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